|Bid||6.88 x 900|
|Ask||7.44 x 800|
|Day's Range||6.77 - 7.39|
|52 Week Range||2.85 - 11.72|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Speaking on today's call will be our CEO, and President, Dr. Rich Murray, who will discuss our progress and key milestones followed by our CMO, Beth Trehu, who will provide an update on our clinical activities. Kim Drapkin will review our third quarter financial results. Before we begin, I would like to remind everyone that today's discussion will include statements about our future expectations, plans, and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Shares of Jounce Therapeutics (NASDAQ: JNCE) were crashing 20.2% lower as of 11:42 a.m. EST on Monday. The big drop came after the company announced that it would not continue patient enrollment in the Emerge phase 2 trial evaluating vopratelimab (vopra) in combination with Bristol Myers Squibb's Yervoy in treating non-small cell lung cancer (NSCLC). This news hit the biotech stock especially hard because vopra is Jounce's lead pipeline candidate.
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...